Dashboard
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 14.67% and Operating profit at 0% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at 0 times
Flat results in Sep 26
Stock is technically in a Bearish range
Risky - Negative EBITDA
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
INR 184 Cr (Micro Cap)
NA (Loss Making)
40
0.00%
-2.36
24.16%
-3.91
Total Returns (Price + Dividend) 
Oxygenta Pharma for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Oxygenta Pharmaceutical Ltd is Rated Strong Sell
Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 September 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock's current position as of 18 November 2026, providing investors with the latest comprehensive analysis.
Read More
Oxygenta Pharmaceutical Ltd Reports Flat Quarterly Performance Amid Margin Pressures
Oxygenta Pharmaceutical Ltd’s latest quarterly results for September 2026 reveal a marked shift in financial momentum, with the company’s growth trajectory flattening after a period of robust expansion. Despite a strong surge in net sales, rising interest expenses and a deteriorating financial trend score have weighed on investor sentiment, prompting a downgrade to a Strong Sell rating.
Read More
Oxygenta Pharmaceutical Ltd is Rated Strong Sell
Oxygenta Pharmaceutical Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 September 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 31 October 2026, providing investors with the latest comprehensive view of the company’s position.
Read More Announcements 
Un-Audited Financial Results For The Quarter And Half-Year Ended 30.09.2026.
10-Nov-2026 | Source : BSEUn-audited Financial Results for the Quarter and Half-year ended 30.09.2026.
Board Meeting Outcome for Outcome Of Board Meeting Held On Tuesday I.E. 10Th November 2026.
10-Nov-2026 | Source : BSEOutcome of Board Meeting held on Tuesday i.e. 10th November 2026.
Board Meeting Intimation for 1. Un-Audited Financial Results For The Quarter And Half Year Ended September 30 2026.
05-Nov-2026 | Source : BSE Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 3 Schemes (0.03%)
Held by 0 FIIs
Virupaksha Organics Limited (56.5%)
Sravani Reddy Gantla (6.78%)
38.27%
Quarterly Results Snapshot (Standalone) - Sep'26 - YoY
YoY Growth in quarter ended Sep 2026 is 134.20% vs 2.07% in Sep 2025
YoY Growth in quarter ended Sep 2026 is 44.42% vs -72.98% in Sep 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 10.55% vs 33.55% in Sep 2024
Growth in half year ended Sep 2025 is -161.61% vs 45.34% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 5.90% vs 105.71% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -94.85% vs 29.13% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 3.37% vs 175.73% in Mar 2025
YoY Growth in year ended Mar 2026 is -70.58% vs -195.98% in Mar 2025